Trial Profile

A superiority study comparing IkT-001Pro to imatinib mesylate for stable-phase Chronic Myelogenous Leukemia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IKT 001PRO (Primary) ; Imatinib
Indications Chronic myeloid leukaemia
Focus Adverse reactions
Sponsors Inhibikase Therapeutics

Most Recent Events

30 Aug 2022 New trial record
26 Aug 2022 According to Inhibikase Therapeutics media release, following the bioequivalence study, Inhibikase will conduct this superiority study comparing the selected dose of IkT-001Pro to 400 mg imatinib mesylate, the current standard-of-care for stable-phase Chronic Myelogenous Leukemia and evaluate the adverse event profile and patient reported outcomes as a measure of superiority over standard-of-care.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com